Business Context and Reporting Period
This Form 8-K Current Report was filed by Exicure, Inc. on April 19, 2021. The filing addresses significant changes to the composition of the Board of Directors and the reconstitution of Board committees in preparation for the 2021 Annual Meeting of Stockholders scheduled for June 1, 2021.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Director Resignations:
- Chad A. Mirkin, Ph.D. notified the Board of his resignation effective April 30, 2021, to pursue other endeavors. He will continue to support the Company in a consulting capacity.
- David R. Walt, Ph.D. previously notified the Board of his intention not to stand for re-election when his term expires at the upcoming Annual Meeting.
- Board Reclassification: The Board size will be eight members following the Annual Meeting. To reclassify directors into three classes of nearly equal size, the following immediate resignations and reappointments occurred:
- Class I (Re-election at 2021 Annual Meeting): Dr. Garofalo, Mr. Sassine, and Dr. Giljohann.
- Class II (Re-election at 2022 Annual Meeting): Dr. Muralidhar and Mr. Sulat.
- Class III (Re-election at 2023 Annual Meeting): Dr. Cleland.
- Committee Reconstitution:
- Audit Committee: Mr. Sulat (Chair), Dr. Garofalo, Mr. Sassine, Mr. Walbert.
- Compensation Committee: Mr. Hau (Chair), Dr. Cleland, Dr. Muralidhar, Dr. Walt (resigning from committee at Annual Meeting).
- Nominating and Corporate Governance Committee: Dr. Muralidhar (Chair), Mr. Hau, Mr. Walbert.
Guidance, Outlook, and Risks
The filing states that no new compensatory plans, contracts, or arrangements were entered into in connection with these resignations and reappointments. The changes were effected solely to reclassify the Board, and director service is deemed uninterrupted. No financial guidance, outlook, or specific risk factors were disclosed in this document.
Key Facts for Investor Verification
- Verify the impact of Dr. Mirkin's departure on the Company's strategic direction, given his transition to a consulting role.
- Confirm the final composition of the Board and committee members at the June 1, 2021 Annual Meeting, specifically regarding Dr. Walt's non-re-election.
- Review the Company's upcoming financial reports (10-Q or 10-K) for financial metrics, as this 8-K contains no financial data.
- Note that David A. Giljohann serves as both Chief Executive Officer and Interim Chief Financial Officer.